Your browser doesn't support javascript.
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR.
Schwarz, Megan; Torre, Denis; Lozano-Ojalvo, Daniel; Tan, Anthony T; Tabaglio, Tommaso; Mzoughi, Slim; Sanchez-Tarjuelo, Rodrigo; Le Bert, Nina; Lim, Joey Ming Er; Hatem, Sandra; Tuballes, Kevin; Camara, Carmen; Lopez-Granados, Eduardo; Paz-Artal, Estela; Correa-Rocha, Rafael; Ortiz, Alberto; Lopez-Hoyos, Marcos; Portoles, Jose; Cervera, Isabel; Gonzalez-Perez, Maria; Bodega-Mayor, Irene; Conde, Patricia; Oteo-Iglesias, Jesús; Borobia, Alberto M; Carcas, Antonio J; Frías, Jesús; Belda-Iniesta, Cristóbal; Ho, Jessica S Y; Nunez, Kemuel; Hekmaty, Saboor; Mohammed, Kevin; Marsiglia, William M; Carreño, Juan Manuel; Dar, Arvin C; Berin, Cecilia; Nicoletti, Giuseppe; Della Noce, Isabella; Colombo, Lorenzo; Lapucci, Cristina; Santoro, Graziano; Ferrari, Maurizio; Nie, Kai; Patel, Manishkumar; Barcessat, Vanessa; Gnjatic, Sacha; Harris, Jocelyn; Sebra, Robert; Merad, Miriam; Krammer, Florian; Kim-Schulze, Seunghee.
  • Schwarz M; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Torre D; Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lozano-Ojalvo D; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tan AT; Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tabaglio T; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Mzoughi S; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • Sanchez-Tarjuelo R; Institute of Molecular and Cell Biology, IMCB, A*STAR, Singapore, Singapore.
  • Le Bert N; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lim JME; Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Hatem S; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tuballes K; National Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
  • Camara C; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • Lopez-Granados E; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • Paz-Artal E; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Correa-Rocha R; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ortiz A; Department of Immunology, University Hospital La Paz-IdiPAZ, Madrid, Spain.
  • Lopez-Hoyos M; Department of Immunology, University Hospital La Paz-IdiPAZ, Madrid, Spain.
  • Portoles J; Department of Immunology, Research Institution, Sanitaria Hospital, Madrid, Spain.
  • Cervera I; Department of Immunology, Ophthalmology and ENT, Complutense University of Madrid, Madrid, Spain.
  • Gonzalez-Perez M; CIBER de Enfermedades Infecciosas (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.
  • Bodega-Mayor I; Laboratory of Immune-Regulation, Research Institute Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Conde P; Department of Nephrology, IIS-Fundación Jimenez Díaz, Madrid, Spain.
  • Oteo-Iglesias J; Department of Immunology, Hospital University of Marqués de Valdecilla-IDIVAL, Santander, Spain.
  • Borobia AM; Department of Nephrology, Hospital of Puerta de Hierro, Madrid, Spain.
  • Carcas AJ; National Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
  • Frías J; National Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
  • Belda-Iniesta C; National Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
  • Ho JSY; National Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
  • Nunez K; National Center for Microbiology, Carlos III Health Institute, Madrid, Spain.
  • Hekmaty S; CIBER de Enfermedades Infecciosas (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.
  • Mohammed K; Clinical Pharmacology, University Hospital La Paz-IDIPAZ, Platform of Clinical Research Units and Clinical Trials, Spain Faculty of Medicine Autonomous University of Madrid, Madrid, Spain.
  • Marsiglia WM; Clinical Pharmacology, University Hospital La Paz-IDIPAZ, Platform of Clinical Research Units and Clinical Trials, Spain Faculty of Medicine Autonomous University of Madrid, Madrid, Spain.
  • Carreño JM; Clinical Pharmacology, University Hospital La Paz-IDIPAZ, Platform of Clinical Research Units and Clinical Trials, Spain Faculty of Medicine Autonomous University of Madrid, Madrid, Spain.
  • Dar AC; Carlos III Health Institute, Madrid, Spain.
  • Berin C; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Nicoletti G; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Della Noce I; Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Colombo L; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lapucci C; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Santoro G; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ferrari M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Nie K; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Patel M; Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Barcessat V; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Gnjatic S; Hyris Limited, London, UK.
  • Harris J; Hyris Limited, London, UK.
  • Sebra R; Hyris Limited, London, UK.
  • Merad M; Genetic Unit, Synlab Italia, Castenedolo, Italy.
  • Krammer F; Genetic Unit, Synlab Italia, Castenedolo, Italy.
  • Kim-Schulze S; IRCCS, SDN, Napoli, Italy.
Nat Biotechnol ; 40(11): 1680-1689, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-1890202
ABSTRACT
Fast, high-throughput methods for measuring the level and duration of protective immune responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here we report the development of two quantitative PCR assays for SARS-CoV-2-specific T cell activation. The assays are rapid, internally normalized and probe-based qTACT requires RNA extraction and dqTACT avoids sample preparation steps. Both assays rely on the quantification of CXCL10 messenger RNA, a chemokine whose expression is strongly correlated with activation of antigen-specific T cells. On restimulation of whole-blood cells with SARS-CoV-2 viral antigens, viral-specific T cells secrete IFN-γ, which stimulates monocytes to produce CXCL10. CXCL10 mRNA can thus serve as a proxy to quantify cellular immunity. Our assays may allow large-scale monitoring of the magnitude and duration of functional T cell immunity to SARS-CoV-2, thus helping to prioritize revaccination strategies in vulnerable populations.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Biotechnol Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: S41587-022-01347-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Biotechnol Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: S41587-022-01347-6